On March 7, Shanghai Junshi Biosciences Co.Ltd(688180) ( Shanghai Junshi Biosciences Co.Ltd(688180) . SH) announced that the company plans to issue A-Shares to specific objects. The fund raised in this offering will not exceed 3.98 billion yuan and the number of shares issued will not exceed 70 million. The net amount after deducting the issuance expenses will be used for innovative drug R & D projects, Shanghai Shanghai Junshi Biosciences Co.Ltd(688180) science and technology headquarters and R & D base projects.
Among them, 3.682 billion yuan will be invested in innovative drug R & D projects, and the remaining 298 million yuan will be allocated to Shanghai Shanghai Junshi Biosciences Co.Ltd(688180) science and technology headquarters and R & D base projectsp align=”center” style=”text-align:center;”> Source: screenshot of announcement
The plan shows that the raised investment projects involved in the issuance to specific objects will help accelerate Shanghai Junshi Biosciences Co.Ltd(688180) clinical research and promote the listing process of relevant products outside China, enhance the synergy between the company’s preclinical research and clinical research, and alleviate the shortage of research, development and operating funds of the company to a certain extent, It is conducive to the realization of the company’s core development strategy and the sustainable and healthy development of production and operation.
Specifically, the company plans to use the raised funds of RMB 3.682 billion for clinical research and preclinical research of innovative drugs, including clinical research and development projects such as js001 follow-up domestic and foreign clinical research and development, js004 domestic and foreign phase III clinical research and development, js111 domestic and foreign clinical research and development, and preclinical Research of other early projects Shanghai Junshi Biosciences Co.Ltd(688180) said that the project will further enrich the pipeline of the company’s drug products under research, quickly promote the domestic and foreign clinical trials of drugs in the clinical stage, promote the development of preclinical drugs, and lay a foundation for accelerating the listing and registration process of products under research.
In addition, the company also plans to establish Shanghai headquarters and R & D center in Shanghai Xi’An International Medical Investment Company Limited(000516) Park in Shanghai Zhangjiang Science City. The total investment of the project is 1.206 billion yuan, and the raised fund is planned to be 298 million yuan. The total area of the project plot is about 24.4 mu, and the total planned construction area is about 78331 m2.
Shanghai Junshi Biosciences Co.Ltd(688180) said that after the completion of the project, it will become the company’s Shanghai R & D center. The center integrates the functions of drug discovery and identification, functional verification, process development and test, and meets the R & D needs of the company’s innovative drugs in the preclinical stage and the office needs of clinical research design and implementation personnel from the level of hardware facilities. The Shanghai R & D center will mainly involve four business segments, including new drug target research, antibody discovery and screening optimization research, production process amplification and optimization technology research, and new biotechnology research.
